Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Observations

An Unusual Case of Secondary Diabetes due to Surreptitious Nasal Steroid Use

  1. Sophie Brochier, MD,
  2. Orsalia Alexopoulou, MD,
  3. Dominique Maiter, MD, PHD and
  4. Martin Buysschaert, MD, PHD
  1. Division of Endocrinology, St. Luc University Hospital, UCL, Brussels, Belgium
  1. Address correspondence to O. Alexopoulou, MD, Endocrinologie, Cliniques Universitaires St. Luc, Avenue Hippocrate 54, UCL 54.74, 1200 Brussels, Belgium. E-mail: orsalia.alexopoulou{at}diab.ucl.ac.be
Diabetes Care 2005 Jun; 28(6): 1535-1536. https://doi.org/10.2337/diacare.28.6.1535
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

A 54-year-old woman with no family or personal history of diabetes was referred for assessment of fasting hyperglycemia (7.6 mmol/l) and asthenia. Medical history included recurrent stomatopharyngeal candidiasis, rectal ulcerations because of abuse of analgesic suppositories, depression, and chronic sinusitis. On physical examination, she had facial plethora, diffuse bruises, cutaneous fragility, normal weight, and mildly elevated blood pressure (140/90 mmHg). An oral glucose tolerance test (OGTT) showed a 120-min plasma glucose value of 16.2 mmol/l. Homeostasis model assessment suggested decreased insulin sensitivity (67%) with intact β-cell function (106%). HbA1c value was 6.8% (3–6%). Anti-GAD, anti-IA2 antibodies, and microalbuminuria were negative.

There were no compelling clinical features to suggest either routine type 1 or type 2 diabetes. The clinical impression was suggestive of a chronic glucocorticoid excess and an ACTH-independent Cushing’s syndrome was confirmed by an abolished circadian cortisol rhythm (444 and 492 nmol/l at 8 and 20 h, respectively), elevated free urinary cortisol excretion (147 μg/day, normal limit <60), a low ACTH concentration (3 pg/ml), and a lack of morning plasma cortisol suppression after both low (355 nmol/l)- and high (467 nmol/l)-dose dexamethasone administration. However, adrenal gland imaging was normal. In this context, the possibility of hidden intake of glucocorticoids was considered. The patient admitted that she had been taking nasal drops containing prednisolone (2.5 mg/ml) at a dose of 30–40 ml per week for at least 5 years to relieve symptoms of chronic sinusitis (mean dose 10–14 mg prednisolone acetate/day). This consumption was surreptitiously continued during evaluation of the hypothalamic-pituitary-adrenal (HPA) axis. After discontinuation of nasal drops, the patient developed secondary adrenal insufficiency (low morning cortisol at 43 nmol/l) and required hydrocortisone treatment. Three months later, a reevaluation showed near normoglycemia (fasting glycemia 4.4 mmol/l, at 120 min of OGTT 7.9 mmol/l) and a normal HPA axis (morning cortisol 364 nmol/l, peak-to-ACTH stimulation 628 nmol/l).

This is the first report of overt Cushing’s syndrome induced by hidden chronic nasal prednisolone administration and complicated by diabetes and withdrawal-induced adrenal insufficiency. There are only a few publications concerning cases of Cushing’s syndrome induced by intranasal administration of steroids, and these seem to occur particularly in children and adolescents taking betamethasone or dexamethasone drops (1–3). In our case, the high cross-reactivity (171%) of prednisolone in the immunoassay used for cortisol measurement (Elecsys 2010) (4) resulted in falsely high cortisol concentrations, making the evaluation of the HPA axis even more complex.

Physicians should be aware of the deleterious effects of chronic use of intranasal steroids and the risks of their uncontrolled discontinuation.

Footnotes

  • DIABETES CARE

References

  1. ↵
    Findlay C, Macdonald JF, Wallace AM, Geddes N, Donaldson MDC: Childhood Cushing’s syndrome induced by betamethasone nose drops, and repeat prescriptions. BMJ 317:739–740, 1998
    OpenUrlFREE Full Text
  2. Kimmerle R: Iatrogenic Cushing’s syndrome due to dexamethasone nasal drops. Am J Med 79:535–537, 1985
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Perry RJ, Findlay CA, Donaldson MDC: Cushing’s syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 87:45–48, 2002
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Roberts RF, Roberts WL: Performance characteristics of five automated serum cortisol immunoassays. Clin Biochem 37:489–493, 2004
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 28 (6)

In this Issue

June 2005, 28(6)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
An Unusual Case of Secondary Diabetes due to Surreptitious Nasal Steroid Use
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
An Unusual Case of Secondary Diabetes due to Surreptitious Nasal Steroid Use
Sophie Brochier, Orsalia Alexopoulou, Dominique Maiter, Martin Buysschaert
Diabetes Care Jun 2005, 28 (6) 1535-1536; DOI: 10.2337/diacare.28.6.1535

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

An Unusual Case of Secondary Diabetes due to Surreptitious Nasal Steroid Use
Sophie Brochier, Orsalia Alexopoulou, Dominique Maiter, Martin Buysschaert
Diabetes Care Jun 2005, 28 (6) 1535-1536; DOI: 10.2337/diacare.28.6.1535
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Weight Gain and Gestational Diabetes Mellitus Is a Sensitive Issue
  • Beneficial Effects of a 4-Week Exercise Program on Plasma Concentrations of Adhesion Molecules
  • Malignant Melanoma Misdiagnosed as a Diabetic Foot Ulcer
Show more Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.